Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry.

Journal Article (Journal Article;Multicenter Study)

Although new multiple myeloma (MM) therapies are effective in alleviating some disease-associated symptoms (e.g. bone pain, fatigue, functional decline), they can result in additional toxicities, further impacting health-related quality of life (HRQoL). Here, we compared HRQoL and safety of lenalidomide-bortezomib-dexamethasone [RVd (n = 445)], bortezomib-melphalan-prednisone [VMP (n = 77)] and Vd or VMP (n = 588) in patients with newly diagnosed MM (NDMM) from the Connect® MM Registry, a large, USA, multicentre, prospective observational cohort study. Functional Assessment of Cancer Therapy-Multiple Myeloma subscale, EuroQol-5D overall score and Bone Pain Inventory HRQoL scores were significantly improved with RVd versus Vd/VMP. Serious adverse event rates were similar in all groups. Treatment with RVd maintained HRQoL in this real-world, largely community-based population of patients with NDMM.

Full Text

Duke Authors

Cited Authors

  • Abonour, R; Rifkin, RM; Gasparetto, C; Toomey, K; Durie, BGM; Hardin, JW; Terebelo, HR; Jagannath, S; Narang, M; Ailawadhi, S; Omel, JL; Lee, HC; Srinivasan, S; Kitali, A; Agarwal, A; Wagner, L; CONNECT MM Registry Investigators,

Published Date

  • April 2021

Published In

Volume / Issue

  • 193 / 1

Start / End Page

  • 93 - 100

PubMed ID

  • 33118614

Pubmed Central ID

  • PMC8048460

Electronic International Standard Serial Number (EISSN)

  • 1365-2141

Digital Object Identifier (DOI)

  • 10.1111/bjh.17131


  • eng

Conference Location

  • England